eXoZymes Posts $9.16M Net Loss, $9.72M Expenses and $3.04M Cash; Files S-3
eXoZymes reported operating expenses increased to $9.72 million in 2025 from $5.93 million while net loss widened to $9.16 million, with cash and equivalents of $3.04 million as of year-end. eXoZymes advanced AI-enhanced cell-free biomanufacturing in NCT and cannabinoid programs and filed an S-3 in January 2026 for next financing.
1. 2025 Financial Performance
eXoZymes recorded operating expenses of $9.72 million in 2025 versus $5.93 million in 2024 and reported a net loss of $9.16 million compared with a $5.86 million loss the prior year. The company held $3.04 million in cash and cash equivalents at year-end, supporting operations into mid-Q2 2026.
2. Technology and Program Progress
During 2025 the AI-enhanced cell-free biomanufacturing platform progressed from concept to pilot scale, delivering strong conversion rates, high purity and improved process control. Programs including NCT and cannabinoid initiatives advanced toward commercialization milestones under the focused product strategy.
3. Strategic Focus and Capital Efficiency
The company shifted its strategy from broad partnership searches to advancing select high-value product programs via spin-outs, joint ventures and licensing deals. Management emphasized a capital-efficient operating model to build mature assets and capture greater long-term value.
4. Financing Readiness and Upcoming Call
Following IPO execution and key validation milestones, eXoZymes filed an S-3 in January 2026 to engage prospective investors ahead of its next financing round. Management will host a conference call today at 5:30 PM Eastern to review developments, anticipated milestones and answer questions.